Cover Image
市场调查报告书

美国的癌症疫苗市场预测 2020年

US Cancer Vaccine Market Outlook 2020

出版商 KuicK Research 商品编码 302600
出版日期 内容信息 英文 420 Pages
商品交期: 最快1-2个工作天内
价格
Back to Top
美国的癌症疫苗市场预测 2020年 US Cancer Vaccine Market Outlook 2020
出版日期: 2015年05月22日 内容信息: 英文 420 Pages
简介

本报告提供美国的癌症疫苗市场概要、癌症的发病率、罹患率、癌症疫苗的价格和医疗费偿付政策、开发平台趋势,以及参与企业的竞争环境汇整。

第1章 癌症疫苗的简介

第2章 癌症疫苗的机制 & 革新

  • 个体遗传型癌症疫苗的机制
  • 细胞癌症疫苗的机制
  • 神经节苷脂抗原型疫苗的机制
  • [月太]癌症疫苗的机制
  • 肿瘤店主相互作用癌症疫苗的机制

第3章 合癌症疫苗输送的佐剂平台

第4章 美国的癌症发病率和罹患率

  • 主要的癌症的发病率
  • 各州发病率
  • 性别发病率
  • 各年龄族群发病率

第5章 美国的癌症疫苗市场预测

  • 目前市场情况
  • 癌症疫苗的临床实验平台分析
  • 价格 & 医疗费偿付政策

第6章 孤儿状态的癌症疫苗

第7章 癌症研究的资金 & 补助金

第8章 美国的癌症疫苗市场动态

  • 有利的市场参数
  • 市场课题

第9章 美国的癌症疫苗市场上未来的成长机会

第10章 美国的癌症疫苗临床实验平台:企业、适应症、各Phase

  • 研究
  • 前临床
  • 临床
  • 第一阶段
  • 第一阶段/第二阶段
  • 第二阶段
  • 第二阶段/第三阶段
  • 第三阶段
  • 登记完毕

第11章 美国的已上市癌症疫苗临床考察

  • 膀胱癌疫苗:ID Biomedical (PACIS)
  • 膀胱癌疫苗:Organon Teknika (OncoTICE)
  • HPV4价值疫苗 (人类乳突病毒4价值疫苗):Merck (Gardasil)
  • HPV2价值疫苗 (人类乳突病毒2价值疫苗):GlaxoSmithKline/MedImmune (Cervarix)
  • 前列腺癌:Dendreon Corporation (Provenge)

第12章 临床实验平台的中止 & 停止的癌症疫苗

  • 没有开发报告
  • 中止
  • 停止

第13章 对癌症疫苗临床实验的FDA法规

  • 早期、后期阶段临床实验检讨事项
  • 早期阶段临床实验检讨事项
  • 后期阶段临床实验检讨事项

第14章 竞争情形

  • Aduro BioTech
  • Advaxis
  • Antigen Express
  • Argos Therapeutics
  • Bavarian Nordic
  • Celldex Therapeutics
  • Cosmo Pharmaceuticals
  • Dendreon Corporation
  • Galena Biopharma
  • Generex Biotechnology
  • Gradalis
  • GSK
  • Merck
  • NewLink Genetics
  • Oxford BioMedica

图表

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录

Escalating cancer incidences have made the investigators to come forth with therapeutics that could reduce high morbidity and mortality rates. Cancer segment has several products belonging to different categories having different pharmacological efficacy. So, it becomes imperative for investigators to develop products that have both high pharmacological and commercialization potential. Numerous cancer therapeutic is available in market but they have limited pharmacological efficacy and high unmet medical necessities prevails across the globe. Vaccination has been successfully employed to treat various infectious diseases and this idea has been extended to treat different malignancies. In past few decades, various malignancies have increased several folds in US due to which regulatory authorities are willing to accept cancer vaccines as a viable option. After hard work of several decades, investigators have been able to successfully market cancer vaccines in US market.

Cancer vaccines could be divided into to two broad categories of prophylactic (preventive) and therapeutic (treatment) segments. In US, cancer vaccines belong to both of these groups have been marketed in past few decades. Food and Drug Administration (FDA) is taking effective measures to offer better medical care to cancer patients. They are willing to try newer modalities due to which pharmaceutical companies are actively engaged for developing them for different malignancies. Due to this reason cancer vaccines got marketing approval in US and in clinical trials they have generated significant data. Increasing demand and higher acceptance rates among patients are expected to increase their sales due to which pharmaceutical companies are actively competing to generate more revenues from this segment. In future, number of clinical trials is expected to increase to develop cancer vaccines for different malignancies. Some of the products are different stages of clinical trials which are expected to be commercialized in US in coming years.

Cancer vaccines for malignancies developed as a result of infectious agents has gained acceptance in past few years and success of HPV vaccines in encourages pharmaceutical companies to invest significantly in this segment. Moreover, FDA has already approved hepatitis B vaccine for hepatic carcinoma but cure for hepatitis C remains elusive. This segment may develop a whole new segment of cancer vaccines and time will tell about success of these measures. In future, it may happen that cancer vaccines for various malignancies caused by infectious agents will become easily available in US. Main emphasis is being given on Kaposi's sarcoma which is Human Immunodeficiency Virus (HIV) associated malignancy. Till date no effective treatment for Kaposi's sarcoma is available but by activating patients' immune system with the help of cancer vaccines it could be treated. In recent years, investigators have been able to find putative link between H. pylori and gastric cancer. These indices have less frequency but these cases are increasing and there are no competitive products in US market as a result of which significant opportunity to churn significant revenues exists for pharmaceutical companies.

US is expected to become one of the largest market for cancer vaccines due to amenable regulatory rules for newly developed medicinal products. FDA is known to provide early marketing approval to products if breakthrough is produced at early stages of clinical trials. This will allow the cancer patients use cancer vaccine for their treatment without waiting for long time. Recently, US has agreed to introduce lung cancer vaccine developed in Cuba to be used in clinical trials for checking its safety and efficacy. If this lung cancer vaccine proves its worth in clinical trials performed in US, then it will get marketing approval. Due to increasing cancer incidences, it has become necessary to take such steps which will help the large population base suffering from different malignancies. Hopefully, pharmaceutical companies will try to take introduce their cancer vaccines as soon as possible in US to occupy major market shares due to which more cancer patients will get highly effective cancer vaccines.

"US Cancer Vaccine Market Outlook 2020" Report Highlight:

  • US Cancer Vaccine Market Analysis
  • Cancer Vaccine with Orphan Status
  • US Cancer Vaccine Clinical Pipeline by Company, Indication & Phase
  • US Cancer Vaccine Clinical Pipeline: 187 Vaccines
  • Clinical Insight of Marketed Cancer Vaccines in US
  • Marketed Cancer Vaccine in US: 5 Vaccines
  • FDA Regulations for Clinical Trials of Cancer Vaccines

Clinical Insight of Marketed Cancer Vaccines in US

  • Bladder Cancer Vaccine - ID Biomedical (PACIS®)
  • Bladder Cancer Vaccine - Organon Teknika (OncoTICE)
  • Human Papillomavirus Vaccine Quadrivalent - Merck (Gardasil®)
  • Human Papillomavirus Vaccine Recombinant Bivalent - GlaxoSmithKlinee (Cervarix®)
  • Prostate Cancer - Dendreon Corporation (Provenge®)

Table of Contents

1. Introduction to Cancer Vaccine

2. Cancer Vaccine Mechanism & Innovations

  • 2.1. Idiotype Cancer Vaccine Mechanism
  • 2.2. Cellular Cancer Vaccines Mechanism
  • 2.3. Ganglioside Antigens based Cancer Vaccines Mechanism
  • 2.4. Peptide Cancer Vaccine Mechanism
  • 2.5. Tumor Host Interaction Cancer Vaccine Mechanism

3. Adjuvants Platforms for Cancer Vaccine Delivery

4. US Cancer Incidence & Prevalence

  • 4.1. Leading Cancer Incidence
  • 4.2. Incidence by State
  • 4.3. Incidence by Gender
  • 4.4. Incidence by Age Group

5. US Cancer Vaccine Market Analysis

  • 5.1. Current Market Scenario
  • 5.2. Cancer Vaccine Clinical Pipeline Analysis
  • 5.3. Pricing & Reimbursement Policy

6. Cancer Vaccine with Orphan Status

7. Cancer Research Funding & Grants

8. US Cancer Vaccine Market Dynamics

  • 8.1. Favorable Market Parameters
  • 8.2. Market Challenges

9. US Cancer Vaccine Market Future Growth Opportunities

10. US Cancer Vaccine Clinical Pipeline by Company, Indication & Phase

  • 10.1. Research
  • 10.2. Preclinical
  • 10.3. Clinical
  • 10.4. Phase-I
  • 10.5. Phase-I/II
  • 10.6. Phase-II
  • 10.7. Phase-II/III
  • 10.8. Phase-III
  • 10.9. Registered

11. Clinical Insight of Marketed Cancer Vaccines in US

  • 11.1. Bladder Cancer Vaccine - ID Biomedical (PACIS®)
  • 11.2. Bladder Cancer Vaccine - Organon Teknika (OncoTICE)
  • 11.3. Human Papillomavirus Vaccine Quadrivalent - Merck (Gardasil®)
  • 11.4. Human Papillomavirus Vaccine Recombinant Bivalent - GlaxoSmithKline/MedImmune (Cervarix®)
  • 11.5. Prostate Cancer - Dendreon Corporation (Provenge®)

12. Discontinued & Suspended Cancer Vaccine in Clinical Pipeline

  • 12.1. No Development Reported
  • 12.2. Discontinued
  • 12.3. Suspended

13. FDA Regulations for Clinical Trials of Cancer Vaccines

  • 13.1. Considerations for both Early and Late Phase Clinical Trials
    • 13.1.1. Patient Population
    • 13.1.2. Monitoring the Immune Response
    • 13.1.3. Biomarkers as Evidence of Efficacy
    • 13.1.4. Adjuvants Used To Stimulate Immune Response
    • 13.1.5. Multi-Antigen Vaccines
    • 13.1.6. Disease Progression/Recurrence Immediately or Shortly After the Initial Administration of Cancer Vaccines
    • 13.1.7. Concomitant & Subsequent Therapies
  • 13.2. Considerations for Early Phase Clinical Trials
    • 13.2.1. Starting Dose & Dosing Schedule
    • 13.2.2. Booster & Maintenance Therapy
    • 13.2.3. Dose Escalation
    • 13.2.4. Single-Arm versus Randomized Phase 2 Trials In Early Development
  • 13.3. Considerations for Late Phase Clinical Trials
    • 13.3.1. Safety Profile from Early Phase Clinical Trials
    • 13.3.2. Endpoints
    • 13.3.3. Statistical Issues
    • 13.3.4. Control Issues
    • 13.3.5. Delayed Vaccine Effect
    • 13.3.6. Autologous Vaccine Trials
    • 13.3.7. Accelerated Approval Regulations

14. Competitive Landscape

  • 14.1. Aduro BioTech
  • 14.2. Advaxis
  • 14.3. Antigen Express
  • 14.4. Argos Therapeutics
  • 14.5. Bavarian Nordic
  • 14.6. Celldex Therapeutics
  • 14.7. Cosmo Pharmaceuticals
  • 14.8. Dendreon Corporation
  • 14.9. Galena Biopharma
  • 14.10. Generex Biotechnology
  • 14.11. Gradalis
  • 14.12. GSK
  • 14.13. Merck
  • 14.14. NewLink Genetics
  • 14.15. Oxford BioMedica

List of Figures

  • Figure 1-1: Categorization & Function of Cancer Vaccines
  • Figure 2-1: Classification of Different Types of Cancer vaccines
  • Figure 5-1: US Cancer Vaccine Market (US$ Billion), 2014-2020
  • Figure 5-2: US Share in Global Cancer Vaccines Market (%), 2014 & 2020
  • Figure 5-3: US Vaccine Markey by Therapeutic & Prophylactic Vaccines, 2014 & 2020
  • Figure 5-4: US Prophylactic Cancer Vaccines Market, (US$ Billion), 2014-2020
  • Figure 5-5: US Therapeutic Cancer Vaccines Market, (US$ Billion), 2014-2020
  • Figure 5-6: US Cancer Vaccine Pipeline by Phase (%), 2015
  • Figure 5-7: US Cancer Vaccine Pipeline by Phase (Number), 2015
  • Figure 5-8: No Development Reported US Cancer Vaccine Pipeline by Phase (%), 2015
  • Figure 5-9: No Development Reported US Cancer Vaccine Pipeline by Phase (Number), 2015
  • Figure 5-10: Discontinued US Cancer Vaccine Pipeline by Phase (%), 2015
  • Figure 5-11: Discontinued US Cancer Vaccine Pipeline by Phase (Number), 2015
  • Figure 5-12: Suspended US Cancer Vaccine Pipeline by Phase (%), 2015
  • Figure 5-13: Suspended US Cancer Vaccine Pipeline by Phase (Number), 2015
  • Figure 14-1: Advaxis Clinical Pipeline
  • Figure 14-2: Argos Therapeutics Clinical Pipeline
  • Figure 14-3: Cosmo Pharmaceuticals Clinical Pipeline
  • Figure 14-4: Gradalis Clinical Pipeline
  • Figure 14-5: NewLink Genetics Clinical Pipeline

List of Tables

  • Table 4-1: Estimated Number of New Cases for Selected Cancers by State, 2015
  • Table 4-2: Estimated Number of Deaths for Selected Cancers by State, 2015
  • Table 4-3: Estimated Number of New Cancer Cases and Deaths by Gender, 2015
  • Table 4-4: Estimated New Cancer Cases by Age (Years), 2015
  • Table 4-5: Estimated Cancer Deaths by Age (Years), 2015
  • Table 6-1: US Orphan Designated Cancer Vaccines
  • Table 7-1: Spending on Cancer Research (US$ Million), 2010-2012
  • Table 7-2: Grants for Cancer Research (US$), 2013
  • Table 7-3: Grants for Cancer Research by States (US$), 2013
  • Table 7-4: Cancer Funding by Area of Research (US$)
  • Table 14-1: Aduro BioTech Cancer Vaccine Pipeline
  • Table 14-2: Aduro BioTech Cancer Immunotherapies
  • Table 14-3: Antigen Express Cancer Vaccine Pipeline
  • Table 14-4: Bavarian Nordic Cancer Vaccine Pipeline
  • Table 14-5: Celldex Therapeutics Cancer Vaccine Pipeline
  • Table 14-6: Dendreon Corporation Cancer Vaccine Pipeline
  • Table 14-7: Galena Biopharma Cancer Vaccine Pipeline
  • Table 14-8: GSK Cancer Vaccine Pipeline
  • Table 14-9: Merck Cancer Vaccine Pipeline
  • Table 14-10: Oxford BioMedica Cancer Vaccine Pipeline
Back to Top